esmo congress, copenhagen 2016 non abstract related … · title presentation 2 tumour evolution...
TRANSCRIPT
![Page 1: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/1.jpg)
1
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Keynote presentations .................................................................................................................................... 2
Basic science and translational research ........................................................................................................ 3
Breast cancer, early stage .............................................................................................................................. 6
Breast cancer, metastatic ............................................................................................................................... 8
CNS tumours ............................................................................................................................................... 10
Developmental therapeutics ......................................................................................................................... 12
Gastrointestinal tumours, colorectal ............................................................................................................ 14
Gastrointestinal tumours, non-colorectal ..................................................................................................... 16
Genitourinary tumours, prostate .................................................................................................................. 18
Genitourinary tumours, non prostate ........................................................................................................... 20
Gynaecological cancers ............................................................................................................................... 22
Haematological Malignancies ..................................................................................................................... 24
Head & neck cancer ..................................................................................................................................... 26
Immunotherapy of cancer ............................................................................................................................ 28
Melanoma and other skin tumours .............................................................................................................. 30
NETs and endocrine tumours ...................................................................................................................... 32
Non-metastatic NSCLC and other thoracic malignancies ........................................................................... 34
NSCLC, metastatic ...................................................................................................................................... 36
Public health and health economics ............................................................................................................. 39
Sarcoma ....................................................................................................................................................... 41
Supportive and palliative care ..................................................................................................................... 43
Congress Highlights..................................................................................................................................... 46
ESMO YO sessions ..................................................................................................................................... 47
Special Session ............................................................................................................................................ 51
Special Session ............................................................................................................................................ 52
Special Session ............................................................................................................................................ 53
Special Session ............................................................................................................................................ 54
Special Session ............................................................................................................................................ 55
Special Session ............................................................................................................................................ 56
Special Session ............................................................................................................................................ 57
Special Session ............................................................................................................................................ 58
![Page 2: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/2.jpg)
2
ESMO Congress, Copenhagen 2016
NON ABSTRACT RELATED PROGRAMME Keynote presentations
Saturday, 8 October 2016 – 13:00-13:45 45 mins
Topic Immunotherapy: From the basic to the clinic
Title The development of checkpoint inhibitors
Chair Rolf A. Stahel, CH
Speaker James P. Allison, US
Sunday, 9 October 2016 – 13:00-13:45 45 mins
Title The art of the possible: Bridging the gap between genomics and patient care?
Chair Richard Marais, UK
Speaker Emile Voest, NL
Monday, 10 October 2016 – 13:00-13:45 45 mins
Title The patient journey: Is cancer cure around the corner?
Chair Fortunato Ciardiello, IT
Speaker Jean-Charles Soria, FR
![Page 3: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/3.jpg)
3
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME Basic science and translational research
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final Title Primary and secondary resistance to targeted therapy and immunotherapy
Speaker Jeffrey Engelman, US
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium 1 Friday, 7 October 2016 – 16:00-17:30 90 mins
Title symposium Adapting clinical trials to tumour biology: Shooting at a moving target
Chair Alberto Bardelli, IT
Co-Chair TBC
Title presentation 1 Introduction
Speaker 1 TBC
Lecture time 1 5’
Title presentation 2 What have we learned from failures?
Speaker 2 Emma Dean, UK
Lecture/disc time 2 20’
Title presentation 3 Master protocols and basket trials: Have we found the answer?
Speaker 3 Keith Flaherty, US
Lecture/disc time 3 20’
Title presentation 4 Modulating responses using CtDNA
Speaker 4 Alberto Bardelli, IT
Lecture/disc time 4 20’
Title presentation 5 New clinical trial design
Speaker 5 Susan Galbraith, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Alberto Bardelli, IT
Lecture/disc time 6 5’
![Page 4: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/4.jpg)
4
Special Symposium 2 Monday, 10 October 2016 – 11:00-12:30 90 mins
Title symposium Using biomarkers to monitor the dynamics of tumour responses to therapy
Chair Joan Seoane, ES
Co-Chair Alberto Sobrero, IT
Title presentation 1 Introduction
Speaker 1 Alberto Sobrero, IT
Lecture time 1 5’
Title presentation 2 Biomarkers of the host
Speaker 2 George Coukos, CH
Lecture/disc time 2 20’
Title presentation 3 Circulating biomarkers to monitor patient responses
Speaker 3 Caroline Dive, UK
Lecture/disc time 3 20’
Title presentation 4 Patient derived models to select treatment
Speaker 4 Joan Seoane, ES
Lecture/disc time 4 20’
Title presentation 5 Using dynamic changes in inflammation to monitor tumour responses
Speaker 5 Paul Tumeh, US
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Joan Seoane, ES
Lecture/disc time 6 5’
Multidisciplinary patient cases Monday, 10 October 2016 – 09:30-10:30 60 mins
Topic Targeting the genes is not enough: The patients and tumour behaviour also matter
Chair Pasi Jånne, US
Title presentation 1 One mutation, many cancers
Speaker 1 David Huntsman, CA
Title presentation 2 Resistance mutations and cell context specific adaptive responses
Speaker 2 Pasi Jånne, US
Title presentation 3 Considering clonal evolution in breast cancer management
Speaker 3 Carlos Caldas, UK
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 5: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/5.jpg)
5
Special session Saturday, 8 October 2016 – 09:15-10:45 90 mins
Title symposium Will we ever conquer resistance?
Chair Daniel Peeper, NL
Co-Chair Joan Seoane, ES
Title presentation 1 Introduction
Speaker 1 Daniel Peeper, NL
Lecture time 1 5’
Title presentation 2 Tumour evolution under the selective pressure of treatment
Speaker 2 Charles Swanton, UK
Lecture/disc time 2 20’
Title presentation 3 Mechanisms of resistance mediated by the tumour stroma
Speaker 3 Erik Sahai, UK
Lecture/disc time 3 20’
Title presentation 4 New approaches to BRAF resistant disease
Speaker 4 Richard Marais, UK
Lecture/disc time 4 20’
Title presentation 5 What can we learn from single patients?
Speaker 5 Daniel Peeper, NL
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Joan Seoane, ES
Lecture/disc time 6 5’
![Page 6: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/6.jpg)
6
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Breast cancer, early stage
Educational session Saturday, 8 October 2016 – 09:00-10:30 90 mins
Topic The neoadjuvant approach in the multidisciplinary setting
Chair Sibylle Loibl, DE
Co-Chair Marco Colleoni, IT
Title presentation 1 Systemic neoadjuvant treatment
Speaker 1 Sibylle Loibl, DE
Lecture/disc time 30’
Title presentation 2 Surgical challenges after neoadjuvant therapy
Speaker 2 Isabel Rubio, ES
Lecture/disc time 30’
Title presentation 3 The impact of tumour stage and response on radiotherapy indications
Speaker 3 Jacques Bernier, CH
Lecture/disc time 30’
Challenge your Expert Sunday, 9 October 2016 – 08:00-09:00 60 mins
Final Title What is the clinical utility of gene expression-based tests in early breast cancer?
Speaker Aleix Prat, ES
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Sunday, 9 October 2016 – 11:00-12:30 90 mins
Title symposium Treatment options in patients with early breast cancer and BRCA mutation or family history of cancer
Chair Hervé Bonnefoi, FR
Co-Chair Andrew Tutt, UK
Title presentation 1 Introduction
Speaker 1 Hervé Bonnefoi, FR
Lecture time 1 5’
Title presentation 2 Surgical options
Speaker 2 Marian Menke-Pluymers, NL
Lecture/disc time 2 20’
Title presentation 3 Systemic therapy
Speaker 3 Andrew Tutt, UK
Lecture/disc time 3 20’
Title presentation 4 Patient's preference
Speaker 4 Karen Benn, IT
Lecture/disc time 4 20’
Title presentation 5 Fertility issues
Speaker 5 Hatem A. Azim, Jr., BE
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Andrew Tutt, UK
Lecture/disc time 6 5’
![Page 7: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/7.jpg)
7
Multidisciplinary patient cases Monday, 10 October 2016 – 09:30-10:30 60 mins
Topic Treatment approaches in elderly patients
Chair Silvio Monfardini, IT
Title presentation 1 Case presentation
Speaker 1 Silvio Monfardini, IT
Title presentation 2 Bringing geriatrics into oncology
Speaker 2 Silvio Monfardini, IT
Title presentation 3 Tailoring local treatment to the elderly
Speaker 3 Ian Kunkler, UK
Title presentation 4 Optimising systemic therapy
Speaker 4 Hans Wildiers, BE
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
![Page 8: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/8.jpg)
8
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Breast cancer, metastatic
Educational session 1 Friday, 7 October 2016 – 14:00-15:30 90 mins
Topic New developments in the management of ER-positive metastatic breast cancer
Chair Giuseppe Curigliano, IT
Co-Chair Robert Coleman, UK
Title presentation 1 Unlocking the pathways of endocrine resistance
Speaker 1 Giuseppe Curigliano, IT
Lecture/disc time 30’
Title presentation 2 Current and emerging treatment approaches: An embarrassment of riches?
Speaker 2 Nadia Harbeck, DE
Lecture/disc time 30’
Title presentation 3 Minimising the toxicities of targeted therapies
Speaker 3 Thomas Bachelot, FR
Lecture/disc time 30’
Educational session 2 Monday, 10 October 2016 – 16:30-18:00 90 mins
Topic HER2+ advanced breast cancer: A few more questions and many more answers
Chair Javier Cortes, ES
Co-Chair Fatima Cardoso, PT
Title presentation 1 Individualising first line treatment options for HER2+ metastatic breast cancer
Speaker 1 Heikki Joensuu, FI
Lecture/disc time 30’
Title presentation 2 Second line, salvage and emerging treatments for HER2+ disease
Speaker 2 Javier Cortes, ES
Lecture/disc time 30’
Title presentation 3 The role of the immune response in HER2+ disease: Is it relevant for patient care?
Speaker 3 Sherene Loi, AU
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Topic How to translate evidence based guidelines into everyday treatment
Final Title Are guidelines necessary for everyday treatment in metastatic breast cancer?
Speaker Fatima Cardoso, PT
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 9: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/9.jpg)
9
Special symposium Sunday, 9 October 2016 – 14:45-16:15 90 mins
Title symposium Triple negative breast cancer: Do we now have something to be positive about?
Chair Elzbieta Senkus, PL
Co-Chair Andrew Tutt, UK
Title presentation 1 Introduction: The current landscape
Speaker 1 Elzbieta Senkus, PL
Lecture time 1 5’
Title presentation 2 Molecular “dissection” of TNBC to identify therapeutic targets
Speaker 2 Fabrice André, FR
Lecture/disc time 2 20’
Title presentation 3 Targeting DNA repair mechanisms
Speaker 3 Rebecca Dent, SG
Lecture/disc time 3 20’
Title presentation 4 Androgen receptor blockade
Speaker 4 Hervé Bonnefoi, FR
Lecture/disc time 4 20’
Title presentation 5 Immunotherapeutic approaches
Speaker 5 Peter Schmid, UK
Lecture/disc time 5 20’
Title presentation 6 Concluding discussion
Speaker 6 Led by Co-Chair
Lecture/disc time 6 5’
Multidisciplinary patient cases Monday, 10 October 2016 - 15:00-16:00 60 mins
Topic Special situations in advanced breast cancer: De novo and limited metastatic disease
Chair Pier Franco Conte, IT
Title presentation 1 Management of brain metastases in breast cancer 1 case
Speaker 1 Nancy Lin, US
Title presentation 2 Case presentation
Speaker 2 Pier Franco Conte, IT
Title presentation 2 Local therapy approaches
Speaker 2 Ian Kunkler, UK
Title presentation 3 Systemic therapy approaches
Speaker 3 Pier Franco Conte, IT
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
![Page 10: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/10.jpg)
10
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
CNS tumours
Educational session 1 Friday, 7 October 2016 – 14:00-15:30 90 mins
Topic Wind of change: Challenges in neuro-oncology in 2016
Chair Alba Brandes, IT
Co-Chair Michael Brada, UK
Title presentation 1 The new WHO classification: Is molecular diagnosis ready for prime time?
Speaker 1 Pieter Wesseling, NL
Lecture/disc time 30’
Title presentation 2 Newly diagnosed and recurrent glioblastoma: Where are we going?
Speaker 2 Alba Brandes, IT
Lecture/disc time 30’
Title presentation 3 Standard and future approaches in the treatment of rare CNS tumours
Speaker 3 Michael Brada, UK
Lecture/disc time 30’
Educational session 2 Saturday, 8 October 2016 – 14:45-16:15 90 mins
Topic Brain metastases: Are we ready for a paradigm shift?
Chair Roger Stupp, CH
Co-Chair Enrico Franceschi, IT
Title presentation 1 The biology of brain metastases: What should we know?
Speaker 1 Manuel Valiente, ES
Lecture/disc time 30’
Title presentation 2 Is the blood brain barrier still a limit for targeted therapies in brain metastases?
Speaker 2 Matthias Preusser, AT
Lecture/disc time 30’
Title presentation 3 The treatment of brain metastases in the era of immuno-oncology
Speaker 3 Roger Stupp, CH
Lecture/disc time 30’
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final title The revolution of molecular diagnosis in anaplastic gliomas
Speaker Wolfgang Wick, DE
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 11: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/11.jpg)
11
Special symposium Sunday, 9 October 2016 – 11:00-12:30 90 mins
Title symposium Moving steps forward: What’s new in the treatment of brain tumours
Chair Patrick Wen, US
Co-Chair Alba Brandes, IT
Title presentation 1 Introduction
Speaker 1 Alba Brandes, IT
Lecture time 1 5’
Title presentation 2 Immunotherapy for glioblastoma: Quo vadis?
Speaker 2 Michael Weller, CH
Lecture/disc time 2 20’
Title presentation 3 Identifying and overcoming challenges in immunotherapy for brain tumours: The iRANO approach
Speaker 3 Patrick Wen, US
Lecture/disc time 3 20’
Title presentation 4 Targeting angiogenesis in high-grade gliomas: The long and winding road
Speaker 4 Evanthia Galanis, US
Lecture/disc time 4 20’
Title presentation 5 How can we deal with the toxicity of new agents?
Speaker 5 Deborah Blumenthal, IL
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Patrick Wen, US
Lecture/disc time 6 5’
Multidisciplinary patient cases Saturday, 8 October 2016 – 11:00-12:00 60 mins
Topic Low grade glioma: Back to the future
Chair Martin J. van den Bent, NL
Title presentation 1 Case presentation
Speaker 1 Martin J. van den Bent, NL
Title presentation 2 The role of surgery in low grade gliomas: Do timing and extent of resection matter?
Speaker 2 Hugues Duffau, FR
Title presentation 3 When and how treat low grade gliomas
Speaker 3 Martin J. van den Bent, NL
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 35’ Discussion
![Page 12: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/12.jpg)
12
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Developmental therapeutics
Educational session Sunday, 9 October 2016 – 09:00-10:30 90 mins
Topic Upgrading your knowledge on how drug development works nowadays
Chair Udai Banerji, UK
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Defining the right dose: When and how
Speaker 1 Jan Schellens, NL
Lecture/disc time 30’
Title presentation 2 To test or not to test: The role of biomarkers in assisting drug development
Speaker 2 Udai Banerji, UK
Lecture/disc time 30’
Title presentation 3 New side effects of novel drugs that you should be aware of
Speaker 3 David Tan, SG
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 09:30-10:30 60 mins
Final Title Genetic essentials for the modern practicing oncologist
Speaker Emile Voest, NL
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Monday, 10 October 2016 - 14:45-16:15 90 mins
Title symposium Drugs you will be using in 2020
Chair Jordi Rodon, ES
Co-Chair Philippe Aftimos, BE
Title presentation 1 Introduction
Speaker 1 Philippe Aftimos, BE
Lecture time 1 5’
Title presentation 2 Antibody-drug conjugates: Drones targeting tumours?
Speaker 2 Bernard Fine, US
Lecture/disc time 2 15’
Title presentation 3 Engineered peptide therapeutics and other protein therapies (bispecific, BITE´s, DARPins…).
Speaker 3 Michael T. Stumpp, CH
Lecture/disc time 3 15’
Title presentation 4 Crafting selective and artisan kinase inhibitors
Speaker 4 Brian Hodous, US
Lecture/disc time 4 15’
Title presentation 5 Using viruses and bacteria to treat cancer
Speaker 5 Ramon Alemany, ES
Lecture/disc time 5 15’
Title presentation 6 Genes to treat a genetic disease such as cancer: RNA therapeutics
Speaker 6 Pierfrancesco Tassone, IT
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Jordi Rodon, ES
Lecture/disc time 7 10’
![Page 13: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/13.jpg)
13
Multidisciplinary patient cases Saturday, 8 October 2016 – 15:00-16:00 60 mins
Topic Precision medicine in the clinic: How do I provide it?
Chair Charles Ferté, FR
Title presentation 1 Patient case presentation
Speaker 1 Philippe Aftimos, BE
Title presentation 2 From raw data to a comprehensive genetic report
Speaker 2 Ana Vivancos, ES
Title presentation 3 From an NGS test to a clinical decision
Speaker 3 Charles Ferté, FR
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 35’ Discussion
![Page 14: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/14.jpg)
14
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Gastrointestinal tumours, colorectal
Educational session 1
Friday, 7 October 2016 – 14:00-15:30 90 mins
Topic Metastatic colorectal cancer: Providing the continuum of care
Chair Christophe Tournigand, FR
Co-Chair Camilla Qvortrup, DK
Title presentation 1 What can be done beyond first line targeted agents: Switch or continue?
Speaker 1 Dirk Arnold, DE
Lecture/disc time 30’
Title presentation 2 Re-introduction: Is it a valid concept?
Speaker 2 Christophe Tournigand, FR
Lecture/disc time 30’
Title presentation 3 On-treatment biomarkers: Do they help to define the best sequence?
Speaker 3 Clara Montagut, ES
Lecture/disc time 30’
Educational session 2
Saturday, 8 October 2016 – 14:45-16:15 90 mins
Topic Hot topics in the adjuvant treatment of colorectal cancer
Chair Julien Taieb, FR
Co-Chair Richard Adams, UK
Title presentation 1 BRAF, KRAS, MSI and gene signatures: Where are we now?
Speaker 1 Ramon Salazar, ES
Lecture/disc time 30’
Title presentation 2 How best to treat adjuvant rectal cancer
Speaker 2 Richard Adams, UK
Lecture/disc time 30’
Title presentation 3 Complex colon cancer patients in the adjuvant setting (to include elderly, stage II, comorbidities)
Speaker 3 Thierry André, FR
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Final Title Synchronous metastatic colorectal cancer: Addressing difficult situations
Speaker Gunnar Folprecht, DE
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 15: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/15.jpg)
15
Special symposium Sunday, 9 October 2016 – 09:00-10:30 90 mins
Title symposium New molecular challenges in CRC
Chair Sabine Tejpar, BE
Co-Chair Per Pfeiffer, DK
Title presentation 1 Introduction
Speaker 1 Per Pfeiffer, DK
Lecture time 1 5’
Title presentation 2 New classification of CRC: “Gone molecular”?
Speaker 2 Daniela Aust, DE
Lecture/disc time 2 15’
Title presentation 3 Liquid biopsies: Ever closer to daily practice?
Speaker 3 Pierre Laurent-Puig, FR
Lecture/disc time 3 15’
Title presentation 4 BRAF mutations: What are the treatment options?
Speaker 4 Fotios Loupakis, IT
Lecture/disc time 4 15’
Title presentation 5 Patients with rare molecular alterations: Do they need a precision approach?
Speaker 5 Salvatore Siena, IT
Lecture/disc time 5 15’
Title presentation 6 Immunotherapy in mCRC: MSI and beyond
Speaker 6 Neil Segal, US
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Sabine Tejpar, BE
Lecture/disc time 7 10’
Multidisciplinary patient cases Monday, 10 October 2016 – 11:00-12:00 60 mins
Topic Liver dominant disease
Chair Thomas Gruenberger, AT
Title presentation 1 Is the potential of cure adequately depicted within tumour boards? (how to best evaluate the potentially resectable patients in this population)
Speaker 1 Thomas Gruenberger, AT
Title presentation 2 What is the best induction, and which post-op therapies should be used? (how to go to surgery with the best medical treatment and if no surgery is performed do we have a standard?)
Speaker 2 Claus-Henning Köhne, DE
Title presentation 3 Radiofrequency and intra-arterial treatments: How to place them (IAT and RFA for selected patients or for everybody?)
Speaker 3 Thierry de Baere, FR
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 16: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/16.jpg)
16
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME Gastrointestinal tumours, non-colorectal
Educational session 1 Friday, 7 October 2016 – 16:00-17:30 90 mins
Topic What is new in liver cancer?
Chair Josep Llovet, ES
Co-Chair Michel Ducreux, FR
Title presentation 1 The biology of liver cancer
Speaker 1 Jessica Zucman-Rossi, FR
Lecture/disc time 30’
Title presentation 2 Stage-dependent management of HCC and news in systemic treatment
Speaker 2 Josep Llovet, ES
Lecture/disc time 30’
Title presentation 3 New developments in locoregional treatment
Speaker 3 Jens Ricke, DE
Lecture/disc time 30’
Educational session 2 Saturday, 8 October 2016 – 16:30-18:00 90 mins
Title symposium Advances in precision medicine of gastric cancer
Chair Yoon-Koo Kang, KR
Co-Chair Yelena Janjigiian, US
Title presentation 1 Genetic and immune signatures of gastric cancer to inform prognosis and clinical decision making
Speaker 1 Axel Hillmer, SG
Lecture/disc time 1 25’
Title presentation 2 Surgical precision: Novel techniques and perspectives
Speaker 2 Christophe Mariette, FR
Lecture/disc time 2 25’
Title presentation 3 Novel drugs: More precise, more efficacious and safer?
Speaker 3 Yelena Janjigian, US
Lecture/disc time 3 25’
Title presentation 4 Conclusions and clinical perspectives
Speaker 4 Yoon-Koo Kang, KR
Lecture/disc time 4 15’
Challenge your Expert Sunday, 9 October 2016 – 08:00-09:00 60 mins
Final Title Challenges in pancreatic cancer
Speaker Manuel Hidalgo, US
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 17: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/17.jpg)
17
Special symposium Saturday, 8 October 2016 – 11:00-12:30 90 mins
Topic Genetics and epigenetics of gastric cancer: What clinicians should know
Chair Fatima Carneiro, PT
Co-Chair Axel Hillmer, SG
Title presentation 1 Introduction
Speaker 1 Axel Hillmer, SG
Lecture time 5’
Title presentation 2 How to detect and manage familial and hereditary gastric cancer
Speaker 2 Fatima Carneiro, PT
Lecture time 20’
Title presentation 3 Genetics of gastric cancer: Clinical implications
Speaker 3 Ian Chau, UK
Lecture time 20’
Title presentation 4 DNA methylation and epigenetic changes in gastric cancer: From bench to bedside
Speaker 4 Toshikazu Ushijima, JP
Lecture time 20’
Title presentation 5 As a clinician, what do I make of this information?
Speaker 5 Per Pfeiffer, DK
Lecture time 20’
Title presentation 6 Conclusion
Speaker 6 Fatima Carneiro, PT
Lecture time 5’
Multidisciplinary patient cases Sunday, 9 October 2016 – 15:00-16:00 60 mins
Topic Biliary tract cancer: Klatskin tumour
Chair Michel Ducreux, FR
Title presentation 1 Case presentation
Speaker 1 Michel Ducreux, FR
Title presentation 2 Role of surgery and transplantation
Speaker 2 René Adam, FR
Title presentation 3 Medical treatment
Speaker 3 Michel Ducreux, FR
Title presentation 4 Radiation
Speaker 4 Christopher Crane, US
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
![Page 18: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/18.jpg)
18
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Genitourinary tumours, prostate
Educational session 1 Friday, 7 October 2016 – 14:00-15:30 90 mins
Topic Imaging in metastatic prostate cancer
Chair Frederic Lecouvet, BE
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 The role of whole body MRI
Speaker 1 Frederic Lecouvet, BE
Lecture/disc time 1 30’
Title presentation 2 The role of PET/CT
Speaker 2 Uwe Haberkorn, DE
Lecture/disc time 2 30’
Title presentation 3 Radiographic progression free survival: A new biomarker of response to treatment?
Speaker 3 Michael Morris, US
Lecture/disc time 3 30’
Educational session 2 Sunday, 9 October 2016 – 11:00-12:30 90 mins
Topic Multimodality treatment for hormone-naïve metastatic prostate cancer
Chair TBC – one of the speakers
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Docetaxel for prostate cancer: Best timing and right patient
Speaker 1 Nick James, UK
Lecture/disc time 1 30’
Title presentation 2 Radiation to the primary tumour in metastatic disease: When and whom
Speaker 2 Alberto Bossi, FR
Lecture/disc time 2 30’
Title presentation 3 Does radical prostatectomy have an impact on long-term outcomes of patients with metastatic prostate cancer?
Speaker 3 Axel Heidenreich, DE
Lecture/disc time 3 30’
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final Title Minimising the complications of ADT and bone disease in prostate cancer
Speaker Matthew Smith, US
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 19: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/19.jpg)
19
Special symposium Monday, 10 October 2016 – 09:00-10:30 90 mins
Title symposium Biomarker strategies to improve the treatment of castration-resistant prostate cancer
Chair David Olmos, ES
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Introduction
Speaker 1 Chair or Co-Chair
Lecture time 1 5’
Title presentation 2 Translating the genomics landscape into clinical practice
Speaker 2 Rob Bristow, CA
Lecture/disc time 2 20’
Title presentation 3 What is the role of CTCs?
Speaker 3 Howard Scher, US
Lecture/disc time 3 20’
Title presentation 4 Using circulating tumour DNA studies to improve the management of prostate cancer patients
Speaker 4 Gert Attard, UK
Lecture/disc time 4 20’
Title presentation 5 Molecularly defining neuroendocrine prostate cancer
Speaker 5 Himisha Beltran, US
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Chair or Co-Chair
Lecture/disc time 6 5’
Multidisciplinary patient cases Monday, 10 October 2016 – 15:00-16:00 60 mins
Topic Oligometastatic disease in prostate cancer patients
Chair Ronald de Wit, NL
Title presentation 1 Radiation with curative intent
Speaker 1 Piet Ost, BE
Title presentation 2 Radical surgical intervention
Speaker 2 Steven Joniau, BE
Title presentation 3 Systemic treatments
Speaker 3 Ronald de Wit, NL
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 20: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/20.jpg)
20
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Genitourinary tumours, non prostate
Educational session Friday, 7 October 2016 – 16:00-17:30 90 mins
Topic Emerging concepts in daily management of urothelial tumours
Chair Aris Bamias, GR
Co-Chair Vincent Khoo, UK
Title presentation 1 How to select systemic therapy in bladder cancer
Speaker 1 Aris Bamias, GR
Lecture/disc time 30’
Title presentation 2 How to interpret genomic reports in the management of urothelial malignancies (focus on bladder)
Speaker 2 Jim Catto, UK
Lecture/disc time 30’
Title presentation 3 Targeted therapies in urothelial malignancies (including cisplatin and new targets)
Speaker 3 Jonathan E. Rosenberg, US
Lecture/disc time 30’
Challenge your Expert Sunday, 9 October 2016 – 08:00-09:00 60 mins
Topic Difficult to treat potentially curable patient
Final Title Topic: Management of poor risk germ cell tumours
Speaker Christian Kollmannsberger, CA
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Monday, 10 October 2016 – 11:00-12:30 90 mins
Title symposium Immunotherapy in GU malignancies
Chair Joaquim Bellmunt, US
Co-Chair Manuela Schmidinger, AT
Title presentation 1 Introduction
Speaker 1 Joaquim Bellmunt, US
Lecture time 1 5’
Title presentation 2 Biology and new immunological targets in GU malignancies
Speaker 2 John Haanen, NL
Lecture/disc time 2 20’
Title presentation 3 Biomarkers of response and progression in (GU) immunotherapy
Speaker 3 Toni Choueiri, US
Lecture/disc time 3 20’
Title presentation 4 Immunotherapy in urothelial cancers
Speaker 4 Joaquim Bellmunt, US
Lecture/disc time 4 20’
Title presentation 5 Immunotherapy in kidney cancer
Speaker 5 Laurence Albiges, FR
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Manuela Schmidinger, AT
Lecture/disc time 6 5’
![Page 21: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/21.jpg)
21
Multidisciplinary patient cases Saturday, 8 October 2016 – 11:00-12:00 60 mins
Topic Complex symptomatic RCC with bone metastasis
Chair Viktor Grünwald, DE
Title presentation 1 Case presentation
Speaker 1 Viktor Grünwald, DE
Title presentation 2 Every patient with bone metastases should be evaluated for surgical intervention
Speaker 2 Axel Bex, NL
Title presentation 3 Local therapy should implement radiotherapy in bone disease
Speaker 3 Vincent Khoo, UK
Title presentation 4 When medical treatment is just enough in bone disease
Speaker 4 Viktor Grünwald, DE
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
![Page 22: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/22.jpg)
22
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Gynaecological cancers
Educational session 1 Saturday, 8 October 2016 – 14:45-16:15 90 mins
Topic Difficult decisions in gynaecological oncology
Chair Isabelle Ray-Coquard, FR
Co-Chair Andres Poveda, ES
Title presentation 1 Adjuvant therapy of endometrial cancer
Speaker 1 Carien Creutzberg, NL
Lecture/disc time 30’
Title presentation 2 Management of vulnerable patients with gynaecological cancers
Speaker 2 Gilles Freyer, FR
Lecture/disc time 30’
Title presentation 3 Rare ovarian tumours: A special focus on sex cord and germ cell tumours
Speaker 3 Isabelle Ray-Coquard, FR
Lecture/disc time 30’
Educational session 2 Monday, 10 October 2016 – 09:00-10:30 90 mins
Topic Advances in targeted therapy in gynaecological cancers
Chair Jonathan Ledermann, UK
Co-Chair Mansoor Mirza, DK
Title presentation 1 Positioning anti-angiogenic therapy in the ovarian cancer treatment pathway
Speaker 1 Philipp Harter, DE
Lecture/disc time 30’
Title presentation 2 PARP inhibitors in ovarian cancer: What are the next steps?
Speaker 2 Jonathan Ledermann, UK
Lecture/disc time 30’
Title presentation 3 Cervical cancer therapy in 2016
Speaker 3 Mansoor Mirza, DK
Lecture/disc time 30’
Challenge your Expert Sunday, 9 October 2016 – 09:30-10:30 60 mins
Session title Genetic counselling
Final Title BRCA testing in ovarian cancer: Who, why, when and how
Presentation 1 BRCA testing to drive therapy in ovarian cancer
Speaker 1 Eric Pujade-Lauraine, FR
Presentation 2 BRCA testing and prevention in ovarian cancer
Speaker 2 Judith Balmaña, ES
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 23: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/23.jpg)
23
Special symposium Sunday, 9 October 2016 – 14:45-16:15 90 mins
Title symposium Personalised medicine in gynaecological cancers
Chair Andres Poveda, ES
Co-Chair Charlie Gourley, UK
Title presentation 1 Introduction
Speaker 1 Andres Poveda, ES
Lecture time 1 5’
Title presentation 2 Immunotherapy in ovarian cancer
Speaker 2 Lana Kandalaft, CH
Lecture/disc time 2 20’
Title presentation 3 Genomic profiling of endometrial cancer
Speaker 3 Xavier Matias-Guiu, ES
Lecture/disc time 3 20’
Title presentation 4 Genomic profiling of ovarian cancer
Speaker 4 Charlie Gourley, UK
Lecture/disc time 4 20’
Title presentation 5 How to test and define HRD positive population in ovarian cancer
Speaker 5 Iain McNeish, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Charlie Gourley, UK
Lecture/disc time 6 5’
Multidisciplinary patient cases Monday, 10 October 2016 – 11:00-12:00 60 mins
Topic Current options for recurrent platinum sensitive ovarian cancer
Chair Antonio González-Martín, ES
Title presentation 1 Case presentation
Speaker 1 Antonio González-Martín, ES
Title presentation 2 Surgery is an option in platinum sensitive recurrence
Speaker 2 Christian Marth, AT
Title presentation 3 How imaging can help select patients for optimal surgery
Speaker 3 Vincent Vandecaveye, BE
Title presentation 4 Sensitive pop and systemic treatment: Which option for which patient?
Speaker 4 Antonio González-Martín, ES
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
![Page 24: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/24.jpg)
24
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Haematological Malignancies
Educational session Monday, 10 October 2016 – 09:15-10:45 90 mins
Topic Rare lymphomas: Recent developments in diagnostic and treatment
Chair Catherine Thieblemont, FR
Co-Chair Armando López-Guillermo, ES
Title presentation 1 Enteropathy associated lymphoma
Speaker 1 Otto Visser, NL
Lecture/disc time 30’
Title presentation 2 Marginal zone lymphoma
Speaker 2 Catherine Thieblemont, FR
Lecture/disc time 30’
Title presentation 3 Waldenström's macroglobulinemia
Speaker 3 Meletios A Dimopoulos, GR
Lecture/disc time 30’
Challenge your Expert Sunday, 8 October 2016 – 08:00-09:00 60 mins
Topic Diagnosis and treatment of myeloma
Final Title Novel criteria for diagnosing multiple myeloma and their therapeutic implications
Speaker Jesus San Miguel, ES
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Saturday, 8 October 2016 – 11:00-12:30 90 mins
Title symposium Emerging therapeutic strategies in lymphoma
Chair Peter Johnson, UK
Co-Chair Andrés J. M. Ferreri, IT
Title presentation 1 Introduction
Speaker 1 Andrés J. M. Ferreri, IT
Lecture time 1 5’
Title presentation 2 Hodgkin’s Lymphoma: How to incorporate novel agents into standard care of treatment
Speaker 2 Peter Johnson, UK
Lecture/disc time 2 20’
Title presentation 3 CLL: Moving towards chemotherapy and free approaches
Speaker 3 Paolo Ghia, IT
Lecture/disc time 3 20’
Title presentation 4 Mantle cell lymphoma: Impact of novel agents on treatment algorithms
Speaker 4 Simon Rule, UK
Lecture/disc time 4 20’
Title presentation 5 Follicular lymphoma: Novel developments beyond chemotherapy
Speaker 5 Eva Kimby, SE
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Peter Johnson, UK
Lecture/disc time 6 5’
![Page 25: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/25.jpg)
25
Multidisciplinary patient cases Sunday, 9 October 2016 – 09:30-10:30 60 mins
Topic CNS Lymphoma
Chair Francesc Graus, ES
Title presentation 1 Primary CNS lymphoma
Speaker 1 Francesc Graus, ES
Title presentation 2 Secondary CNS lymphoma
Speaker 2 Andrés J. M. Ferreri, IT
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 40’ Discussion
![Page 26: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/26.jpg)
26
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Head & neck cancer
Educational session Sunday, 9 October 2016 – 14:45-16:15 90 mins
Topic Induction chemotherapy: Is there any new data to revisit an inconclusive approach?
Chair Marco Merlano, IT
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 New data from meta-analysis
Speaker 1 Wilfried Budach, DE
Lecture/disc time 30’
Title presentation 2 Emerging clinical trial data
Speaker 2 Marco Merlano, IT
Lecture/disc time 30’
Title presentation 3 Induction chemotherapy: Is there any new data from randomized trials to revisit an inconclusive approach?
Speaker 3 Jean Bourhis, FR
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Topic Rare tumours in HNC: A practical approach
Final Title Management of sinonasal tumours
Speaker Paolo Bossi, IT
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Sunday, 9 October 2016 – 09:00-10:30 90 mins
Title symposium Translating tumour biology into novel therapeutic approaches in HNSCC
Chair Robert L. Ferris, US
Co-Chair Amanda Psyrri, GR
Title presentation 1 Introduction
Speaker 1 Amanda Psyrri, GR
Lecture time 1 5’
Title presentation 2 Targeting tumour hypoxia
Speaker 2 Vincent Grégoire, BE
Lecture/disc time 2 20’
Title presentation 3 Comparison of the genetic landscape of HPV+ and HPV- head and neck cancers
Speaker 3 Paul Brennan, UK
Lecture/disc time 3 20’
Title presentation 4 The role of immunotherapy in HNSCC
Speaker 4 Robert L. Ferris, US
Lecture/disc time 4 20’
Title presentation 5 Novel therapeutic strategies in EBV associated NPC
Speaker 5 Anthony Chan, HK, CN
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Robert L. Ferris, US
Lecture/disc time 6 5’
![Page 27: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/27.jpg)
27
Multidisciplinary patient cases Monday, 10 October 2016 – 16:30-17:30 60 mins
Topic Challenges in the management of HPV- associated OPC
Chair Danny Rischin, AU
Title presentation 1 Early stage HPV positive OPC patient (minimally invasive surgery vs Radiotherapy)
Speaker 1 Christian Simon, CH
Title presentation 2 Locally advanced HPV positive OPC: Selection of deintensification candidates and deintensification strategies
Speaker 2 Danny Rischin, AU
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 40’ Discussion
![Page 28: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/28.jpg)
28
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Immunotherapy of cancer
Educational session Friday, 7 October 2016 – 10:15-11:45 90 mins
Topic Cancer Immunotherapy (CIT): What every oncologist should know
Chair Ignacio Melero, ES
Co-Chair Sjoerd van der Burg, NL
Title presentation 1 Back to the basics
Speaker 1 Sjoerd van der Burg, NL
Lecture/disc time 15’
Title presentation 2 Cancer vaccines: Can we make them work? (presentation to start with case)
Speaker 2 Kees Melief, NL
Lecture/disc time 25’
Title presentation 3 T cell therapy: For whom and when? (presentation to start with case)
Speaker 3 Inge Marie Svane, DK
Lecture/disc time 25’
Title presentation 4 Immune checkpoints: Do we really know how they work? (presentation to start with case)
Speaker 4 Ignacio Melero, ES
Lecture/disc time 25’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Topic Immunotherapy: The latest developments
Final Title Management of side effects
Speaker Georgina Long, AU
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 29: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/29.jpg)
29
Special symposium Saturday, 8 October 2016 – 09:00-10:30 90 mins
Title symposium Whither immunotherapy?
Chair Ignacio Melero, ES
Co-Chair Mario Colombo, IT
Title presentation 1 Introduction
Speaker 1 Ignacio Melero, ES
Lecture time 1 5’
Title presentation 2 Tumour landscape: Clues for new targets
Speaker 2 Jerome Galon, FR
Lecture/disc time 2 20’
Title presentation 3 Converting a non-immunogenic into an immunogenic tumour
Speaker 3 Thomas Gajewski, US
Lecture/disc time 3 20’
Title presentation 4 Inflamed phenotype and immunotherapy: The H&N case
Speaker 4 Tanguy Seiwert, US
Lecture/disc time 4 20’
Title presentation 5 Combining immunotherapy: (ir)rational choices
Speaker 5 James Larkin, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Mario Colombo, IT
Lecture/disc time 6 5’
Multidisciplinary patient cases Sunday, 9 October 2016, 09:30-10:30
60mins
Topic Can immunotherapy be given safely to special subtypes of cancer patients?
Chair Paul Nathan, UK
Title presentation 1 Auto-immunity and cancer immunotherapy Bladder cancer patients treated with checkpoint inhibitors
Speaker 1 Paul Nathan, UK
Title presentation 2 Brain metastases and cancer immunotherapy Renal cell cancer patients treated with check point inhibitors
Speaker 2 Paolo Ascierto, IT
Title presentation 3 Chronic viral infections and cancer immunotherapy
Speaker 3 Emanuela Romano, FR
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 30: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/30.jpg)
30
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Melanoma and other skin tumours
Educational session Sunday, 9 October 2016 – 14:45-16:15 90 mins
Topic Melanoma: Does the run of success continue?
Chair Dirk Schadendorf, DE
Co-Chair Paul Lorigan, UK
Title presentation 1 New checkpoints
Speaker 1 Jeffrey Weber, US
Lecture/disc time 30’
Title presentation 2 Neoantigens
Lecture/disc time 30’
Speaker 2 Dirk Schadendorf, DE
Title presentation 3 Novel immunotherapeutic constructs
Speaker 3 Speaker TBC
Lecture/disc time 30’
Challenge your Expert Sunday, 9 October 2016 – 08:00-09:00 60 mins
Final Title Will there be a place for adoptive T-cell therapy in the checkpoint inhibitors?
Speaker Jacob Schachter, IL
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Saturday, 8 October 2016 – 11:00-12:30 90 mins
Title symposium Optimal combination and sequencing strategies in melanoma
Chair Reinhard Dummer, CH
Co-Chair Paolo Ascierto, IT
Title presentation 1 Introduction
Speaker 1 Reinhard Dummer, CH
Lecture time 1 5’
Title presentation 2 Rationale for combining
Speaker 2 Paolo Ascierto, IT
Lecture/disc time 2 20’
Title presentation 3 Rationale for sequencing
Speaker 3 Caroline Robert, FR
Lecture/disc time 3 20’
Title presentation 4 Can biomarkers help make the decision?
Speaker 4 Antoni Ribas, US
Lecture/disc time 4 20’
Title presentation 5 A closer look at the current guidelines on sequencing and combination (including new ESMO guidelines, how to move forward, clinical trial design)
Speaker 5 Paul Lorigan, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Paolo Ascierto, IT
Lecture/disc time 6 5’
![Page 31: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/31.jpg)
31
Multidisciplinary patient cases Sunday, 9 October 2016 – 16:30-17:30 60 mins
Topic Continuum of management of stage IV in melanoma
Chair Olivier Michielin, CH
Title presentation 1 First-line
Speaker 1 Christian Blank, NL
Title presentation 2 Second-line
Speaker 2 Christoph Hoeller, AT
Title presentation 3 Brain metastasis
Speaker 3 Lars Bastholt, DK
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 32: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/32.jpg)
32
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
NETs and endocrine tumours
Educational session Monday, 10 October 2016 - 14:45-16:15 90 mins
Topic Management of advanced radioactive-iodine(RAI) refractory differentiated thyroid cancer (DTC)
Chair Martin Schlumberger, FR
Co-Chair Jaume Capdevila, ES
Title presentation 1 New insights in molecular biology of thyroid cancer
Speaker 1 Xavier Matias-Guiu, ES Lecture/disc time 30’
Title presentation 2 Enhancing iodine uptake in DTC
Speaker 2 Jaume Capdevila, ES
Lecture/disc time 30’
Title presentation 3 Treatment options in advanced RAI-refractory DTC
Speaker 3 Martin Schlumberger, FR
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 09:30-10:30 60 mins
Topic Adrenocortical tumours
Final Title What are genomics adding to patient management?
Speaker Jérôme Bertherat, FR
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Sunday, 9 October 2016 – 16:30-18:00 90 mins
Title symposium Precision medicine in NETs: Myth or reality?
Chair Rocio Garcia-Carbonero, ES
Co-Chair Kjell Öberg, SE
Title presentation 1 Introduction
Speaker 1 Rocio Garcia-Carbonero, ES
Lecture time 1 5’
Title presentation 2 Molecular tumour profiling and upcoming biomarkers: Will they help to deliver personalised medicine?
Speaker 2 Tim Meyer, UK
Lecture/disc time 2 15’
Title presentation 3 Minimally invasive surgery: Does it improve precision?
Speaker 3 Massimo Falconi, IT
Lecture/disc time 3 15’
Title presentation 4 Nuclear medicine: What do novel isotopes add to the treatment of NETs?
Speaker 4 Lisa Bodei, IT
Lecture/disc time 4 15’
Title presentation 5 Targeted drugs: Where are we now?
Speaker 5 Marianne Pavel, DE
Lecture/disc time 5 15’
Title presentation 6 Targeted drugs: Where are we heading to?
Speaker 6 Eric Raymond, CH
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Kjell Öberg, SE
Lecture/disc time 7 5’
![Page 33: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/33.jpg)
33
Multidisciplinary patient cases Saturday, 8 October 2016 – 09:30-10:30 60 mins
Topic Pulmonary NETs
Chair James Yao, US
Title presentation 1 The grey zone in between intermediate and high grade NENs: A particular case
Speaker 1 Guido Rindi, IT
Title presentation 2 The minimal surgical approach for lung carcinoids: Pros and cons
Speaker 2 Manuel Garcia-Yuste, ES
Title presentation 3 The evolving landscape of systemic therapy for well differentiated neuroendocrine tumours of the lung
Speaker 3 James Yao, US
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 34: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/34.jpg)
34
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Non-metastatic NSCLC and other thoracic malignancies
Educational session Friday, 7 October 2016 – 16:00-17:30 90 mins
Topic Optimal treatment of stage III NSCLC
Chair Johan Vansteenkiste, BE
Co-Chair Dirk de Ruysscher, NL
Title presentation 1 Which induction therapy for potentially resectable cases? (large volume to be included)
Speaker 1 Wilfried Eberhardt, DE
Lecture/disc time 30’
Title presentation 2 Which systemic therapy in concurrent chemoradiotherapy? (large volume to be included)
Speaker 2 Johan Vansteenkiste, BE
Lecture/disc time 30’
Title presentation 3 Which radiotherapy in concurrent chemoradiotherapy? (large volume to be included)
Speaker 3 Suresh Senan, NL
Lecture/disc time 30’
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final Title Fragile patients with non-metastatic lung cancer: Facts and myths
Speaker Judith van Loon, NL
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Saturday, 8 October 2016 – 09:15-10:45 90 mins
Title symposium Lung cancer early detection and prevention
Chair Jesper Holst Pedersen, DK
Co-Chair Samuel Janes, UK
Title presentation 1 Introduction
Speaker 1 Samuel Janes, UK
Lecture time 1 5’
Title presentation 2 The NELSON trial
Speaker 2 Harry de Koning, NL
Lecture/disc time 2 20’
Title presentation 3 How to implement the NELSON trial
Speaker 3 Samuel Janes, UK
Lecture/disc time 3 20’
Title presentation 4 Defining risk populations with biomarkers
Speaker 4 Jesper Holst Pedersen, DK
Lecture/disc time 4 20’
Title presentation 5 Smoking cessation
Speaker 5 Haseem Ashraf, DK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Jesper Holst Pedersen, DK
Lecture/disc time 6 5’
![Page 35: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/35.jpg)
35
Multidisciplinary patient cases Sunday, 9 October 2016 – 09:30-10:30 60 mins
Topic How to approach a patient with oligometastatic NSCLC
Chair Merina Ahmed, UK
Title presentation 1 A simple case
Speaker 1 Merina Ahmed, UK
Title presentation 2 A difficult case
Speaker 2 Niels Reinmuth, DE
Title presentation 3 An impossible case
Speaker 3 Jens Benn Soerensen, DK
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 36: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/36.jpg)
36
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
NSCLC, metastatic
Educational session 1 Monday, 10 October 2016 – 14:45-16:15 90 mins
Topic The earthquake of immunotherapy in lung cancer
Chair Luis Paz-Ares, ES
Co-Chair Solange Peters, CH
Title presentation 1 Current results of immunotherapy in thoracic oncology
Speaker 1 Luis Paz-Ares, ES
Lecture/disc time 25’
Title presentation 2 Can we select the right patient for immunotherapy in NSCLC? The clinician’s point of view
Speaker 2 Silvia Novello, IT
Lecture/disc time 20’
Title presentation 3 Can we select the right patient for immunotherapy in NSCLC? The pathologist’s point of view
Speaker 3 Ming Tsao, CA
Lecture/disc time 20’
Title presentation 4 Management of side effects of immunotherapy
Speaker 4 Martin Reck, DE
Lecture/disc time 25’
Educational session 2 Monday, 10 October 2016 – 16:30-18:00 90 mins
Topic Next generation small molecule inhibitors
Chair Tony S. K. Mok, HK, CN
Co-Chair TBC
Title presentation 1 Third generation EGFR TKI’s
Speaker 1 Tony S. K. Mok, HK, CN
Lecture/disc time 30’
Title presentation 2 Novel ALK inhibitors
Speaker 2 Solange Peters, CH
Lecture/disc time 30’
Title presentation 3 Novel targets in NSCLC and the compounds to combat them
Speaker 3 Greg Riely, US
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Final Title Lights and shadows in targeting KRAS driven lung cancer
Speaker Påsi Janne, US
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 37: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/37.jpg)
37
Special symposium Saturday, 8 October 2016 – 11:00-12:30 90 mins
Title symposium A molecular profile in NSCLC patients: How? When? Why?
Chair Fabrice Barlesi, FR
Co-Chair Fiona Blackhall, UK
Title presentation 1 Introduction
Speaker 1 Fiona Blackhall, UK
Lecture time 1 5’
Title presentation 2 Molecular profiling for precision lung cancer
Speaker 2 Roman Thomas, DE
Lecture/disc time 2 20’
Title presentation 3 Organisation: Local, regional and national
Speaker 3 Fabrice Barlesi, FR
Lecture/disc time 3 20’
Title presentation 4 Clinical application of serial molecular biomarker monitoring
Speaker 4 Stephen Finn, IE
Lecture/disc time 4 20’
Title presentation 5 Getting the right drug to the right patient based upon molecular profiling
Speaker 5 Jean-Charles Soria, FR
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Fabrice Barlesi, FR
Lecture/disc time 6 5’
Special session Monday, 10 October 2016 - 14:45-16:15 90 mins
Title symposium Liquid biopsies
Chair Peter Meldgaard, DK
Co-Chair Rafal Dziadziuszko, PL
Title presentation 1 Introduction
Speaker 1 Peter Meldgaard, DK or Rafal Dziadziuszko, PL
Lecture time 1 5’
Title presentation 2 Solid tumour, liquid biopsy: Can blood samples give us the answers?
Speaker 2 Dennis (Yuk-Ming) Lo, HK, CN
Lecture/disc time 2 25’
Title presentation 3 Tracking changes: monitoring evolution of disease through circulating free DNA
Speaker 3 Peter Meldgaard, DK
Lecture/disc time 3 25’
Title presentation 4 Blood-based tumour genomics: Technological advances
Speaker 4 Tom Wurdinger, NL
Lecture/disc time 4 25’
Title presentation 5 Conclusions and clinical perspectives
Speaker 5 Peter Meldgaard, DK or Rafal Dziadziuszko, PL
Lecture/disc time 5 10’
![Page 38: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/38.jpg)
38
Multidisciplinary patient cases Saturday, 8 October 2016 – 16:30-17:30 60 mins
Topic Definition and management of oligoprogression during treatment with TKI inhibitors
Chair Egbert Smit NL
Title presentation 1 Practicalities and risks of biopsy
Speaker 1 Josephine Barry, IE
Title presentation 2 Optimal genome profiling for re-biopsy of TKI resistant tumour
Speaker 2 Keith Kerr, UK
Title presentation 3 The perspective of the oncologist
Speaker 3 Egbert Smit NL
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 39: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/39.jpg)
39
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Public health and health economics
Educational session 1 Sunday, 9 October 2016 – 16:30-18:00 90 mins
Topic Bad luck or bad knowledge? Evidence-based cancer prevention approaches
Chair Jack Cuzick, UK
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Where to give prevention advice
Speaker 1 Henrik Grönberg, SE
Lecture/disc time 30’
Title presentation 2 Proven interventions
Speaker 2 Silvia Franceschi, FR
Lecture/disc time 30’
Title presentation 3 Unproven interventions
Speaker 3 Gareth Evans, UK
Lecture/disc time 30’
Educational session 2 Monday, 10 October 2016 - 14:45-16:15 90 mins
Topic Straightforward options for earlier detection and treatment of challenging cancer types
Chair Harry de Koning, NL
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Review of all cancers
Speaker 1 Harry de Koning, NL
Lecture/disc time 30’
Title presentation 2 Ovarian cancer prevention: Are we finally there?
Speaker 2 Speaker TBC
Lecture/disc time 30’
Title presentation 3 Novel insights into Barrett's oesophagus
Speaker 3 Massimiliano di Pietro, UK
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Final Title The development of novel anticancer drugs: How to raise the bar in oncology
Speaker Alberto Sobrero, IT
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 40: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/40.jpg)
40
Special symposium Monday, 10 October 2016 – 11:00-12:30 90 mins
Title symposium Streamlining the equitable delivery of anti-cancer drugs: Sharing common grounds for a pan-European vision of value
Chair Rosa Giuliani, IT
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Introduction
Speaker 1 Co-chair
Lecture time 1 5’
Title presentation 2 Equitable and affordable cancer care: Is Europe a union for real?
Speaker 2 Richard Sullivan, UK
Lecture/disc time 2 15’
Title presentation 3 How the European Commission's HTA initiative and the HTA network can promote consistent assessment of cancer care treatments in the EU
Speaker 3 Andrzej Rys, BE
Lecture/disc time 3 15’
Title presentation 4 The EMA’s initiatives to speed up access to valuable cancer drugs: Adaptive pathways and flexible approaches
Speaker 4 Francesco Pignatti, UK
Lecture/disc time 4 15’
Title presentation 5 Industry’s initiatives to reduce inequities and increase access to valuable cancer care: Myth or reality?
Speaker 5 Richard Bergstrom, US
Lecture/disc time 5 15’
Title presentation 6 ESMO’s initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing on the magnitude of benefit
Speaker 6 Elisabeth de Vries, NL
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Rosa Giuliani, IT
Lecture/disc time 7 10’
![Page 41: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/41.jpg)
41
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Sarcoma
Educational session Sunday, 9 October 2016 – 14:45-16:15 90 mins
Topic Desmoid tumours in 2016
Chair Dirk Strauss, UK
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Molecular pathology tools
Speaker 1 Frederic Chibon, FR
Lecture/disc time 30’
Title presentation 2 Local treatments
Speaker 2 Dirk Strauss, UK
Lecture/disc time 30’
Title presentation 3 Systemic treatments beyond chemotherapy and TKIs
Speaker 3 Bernd Kasper, DE
Lecture/disc time 30’
Challenge your Expert Saturday, 8 October 2016 – 09:30-10:30 60 mins
Final Title Challenges in bone sarcoma
Speaker Stefan Bielack, DE
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Saturday, 8 October 2016 – 16:30-18:00 90 mins
Title symposium Personalising treatment for sarcoma
Chair Olivier Mir, FR
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Introduction
Speaker 1 Co-chair
Lecture time 1 5’
Title presentation 2 Deep sequencing in sarcoma: The pathologist’s perspective
Speaker 2 Paolo dei Tos, IT
Lecture/disc time 2 15’
Title presentation 3 Treatment according to histological subtypes
Speaker 3 Silvia Stacchiotti, IT
Lecture/disc time 3 15’
Title presentation 4 Individualising radiation therapy (use / non-use)
Speaker 4 Rick Haas, NL
Lecture/disc time 4 15’
Title presentation 5 Molecular profiling for patients with STS
Speaker 5 Antoine Italiano, FR
Lecture/disc time 5 15’
Title presentation 6 Personalising treatment of bone sarcoma
Speaker 6 Enrique de Alava, ES
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Olivier Mir, FR Lecture/disc time 7 10’
![Page 42: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/42.jpg)
42
Multidisciplinary patient cases Sunday, 9 October 2016 – 11:00-12:00 60 mins
Topic Systemic treatment for atypical GIST patients
Chair Winette van der Graaf, NL
Title presentation 1 Frail elderly
Speaker 1 Robin Jones, UK
Title presentation 2 Drug interactions
Speaker 2 Olivier Mir, FR
Title presentation 3 Local treatments in oligometastatic disease
Speaker 3 Alessandro Gronchi, IT
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 43: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/43.jpg)
43
ESMO Congress, Copenhagen 2016
NON ABSTRACT RELATED PROGRAMME Supportive and palliative care
Educational session Sunday, 9 October 2016 – 16:30-18:00 90 mins
Topic Prophylaxis and treatment of symptoms in oncology
Chair Karin Jordan, DE
Co-Chair Fausto Roila, IT
Title presentation 1 Chemotherapy induced nausea and vomiting focusing on the updated MASCC/ESMO guidelines
Speaker 1 Karin Jordan, DE
Lecture/disc time 30’
Title presentation 2 Diagnosis and therapy of patients with febrile neutropenia
Speaker 2 Georg Maschmeyer, DE
Lecture/disc time 30’
Title presentation 3 Assessment and therapy of anxiety and depression
Speaker 3 Jon Håvard Loge, NO
Lecture/disc time 30’
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final Title Neurotoxicities assessment, prophylaxis and treatment
Chair Marie Fallon, UK
Speaker Maija Haanpää, FI
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
![Page 44: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/44.jpg)
44
Special symposium Monday, 10 October 2016 – 09:15-10:45 90 mins
Title symposium Clinical challenges and patient needs based defined supportive and palliative interventions delivered by competent multidisciplinary professionals
Chair Florian Strasser, CH
Co-Chair Florian Scotté, FR
Title presentation 1 Introduction
Speaker 1 Florian Scotté, FR
Lecture time 1 5’
Title presentation 2 Integrated care pathways
Speaker 2 Stein Kaasa, NO
Lecture/disc time 2 20’
Title presentation 3 Evidence-based supportive care interventions
Speaker 3 Jørn Herrstedt, DK
Lecture/disc time 3 20’
Title presentation 4 Evidence-based palliative care interventions
Speaker 4 Florian Strasser, CH
Lecture/disc time 4 20’
Title presentation 5 Utilising the available multidisciplinary and interprofessional work force for optimal patient care
Speaker 5 Dorothy Keefe, AU
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Florian Scotté, FR and Florian Strasser, CH
Lecture/disc time 6 5’
Multidisciplinary patient cases Saturday, 8 October 2016 – 15:00-16:00 60 mins
Topic Pain from bone metastases
Co-Chairs (& spkrs) Daniele Santini, IT
Title presentation 1 The medical treatment of bone metastases
Speaker 1 Daniele Santini, IT
Title presentation 2 The role of radiotherapy in the control of bone pain
Speaker 2 Petra Feyer, DE
Title presentation 3 Analgesic multimodal management according to risk factors of cancer pain
Speaker 3 Eija Kalso, FI
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
![Page 45: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/45.jpg)
45
Special Session Friday, 7 October 2016 – 16:00-17:30 90 mins (1h30)
Title symposium
Early detection of cachexia, multimodal intervention and results
Co-Chair
Matti Aapro, CH
Co-Chair
Karin Jordan, DE
Title presentation 1
The role of nutritional support during radio-/chemotherapy
Speaker 1
Jann Arends, DE
Lecture time 1
20’
Title presentation 2
New drugs to treat patients with cancer anorexia cachexia syndrome
Speaker 2
Carla Ripamonti, IT
Lecture time 2
20’
Title presentation 3
The evidence of physical activity interventions during radio-/chemotherapy
Speaker 3
Matthew Maddocks, UK
Lecture time 3
20’
Title presentation 4
Elderly patients: Often malnourished
Speaker 4
Matti Aapro, CH
Lecture time 4
20’
Title presentation 5
General discussion: How to integrate cachexia management in routine cancer care
Speaker 5
All
Lecture time 5
10’
![Page 46: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/46.jpg)
46
ESMO Congress, Copenhagen 2016 Congress Highlights
Congress Highlights Session 1 – The best of the ESMO 2016 Congress Tuesday, 11 October 2016 – 09:00-12:20 Chair part 1: Andrés Cervantes, ES Chair part 2: Fortunato Ciardiello, IT
09:00 20 Breast cancer, early stage Marco Colleoni, IT
09:20 20 Breast cancer, metastatic Robert E. Coleman, UK
09:40 20 Basic science and translational research Govindan Ramaswamy, US
10:00 20 CNS tumours Enrico Franceschi, IT
10:20 20 NETs and endocrine tumours Juan Valle, UK
10:40 20 Break
11:00 20 GU prostate Eleni Efstathiou, GR
11:20 20 GU non-prostate Andrea Necchi, IT
11:40 20 Non-metastatic NSCLC and other thoracic malignancies Dirk de Ruysscher, NL
12:00 20 NSCLC, metastatic Rafal Dziadzuszko, PL
12:20 20 Developmental therapeutics Christopher Twelves, UK
12:40 CLOSE
Congress Highlights Session 2 – The best of the ESMO 2016 Congress Tuesday, 11 October 2016 – 09:00-12:30 Chair part 1: Alberto Sobrero, IT Chair part 2: Josep Tabernero, ES
09:00 20 GI, colorectal Julien Taieb, FR
09:20 20 GI, non colorectal Arnaud Roth, CH
09:40 20 Sarcoma Sebastian Bauer, DE
10:00 20 Gynaecological cancers Cristiana Sessa, CH
10:20 20 Supportive and palliative care Florian Scotté, FR
10:40 20 Break
11:00 20 Head and neck cancer Amanda Psyrri, GR
11:20 20 Public health and health economics Rosa Giuliani, IT
11:40 20 Immunotherapy of cancer John Haanen, NL
12:00 20 Melanoma and other skin tumours Reinhard Dummer, CH
12:20 20 Haematological malignancies Steven Le Gouill, FR
12:40 CLOSE
![Page 47: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/47.jpg)
47
ESMO Congress, Copenhagen 2016 ESMO YO sessions
YO Masterclass Sunday, 9 October 2016, 14:15-17:15 180’ (incl. 20’ coffee break)
Title session Harnessing the immune system for cancer therapy
Chair Matthias Preusser, AT
Co-chair Raffaele Califano, UK
Title presentation 1
Basic immunology for the medical oncologist
Speaker 1 Ignacio Melero, ES
Session Shooter 1 Leticia de Mattos-Arruda, ES
Lecture/discussion time
40’ (25’presentation plus 15’ discussion)
Title presentation 2
Immune checkpoint blockade and impact on clinical practice
Speaker 2 Michael Postow, US
Session Shooter 2 Jesus Corral, ES
Lecture/discussion time
40’ (25’ presentation plus 15’ discussion)
Coffee Break
20’
Title presentation 3
Combining immunotherapies with other anti-cancer therapies
Speaker 3 Paul Lorigan, UK
Session Shooter 3 Mila Petrova, BG
Lecture/discussion time
40’ (25’ presentation plus 15’ discussion)
Title presentation 4
Managing toxicities – case based discussions
Speaker 4 Jeffrey Weber, US
Session Shooter 4 Ramon de Mello, PT
Lecture/discussion time
40’ (25’ presentation plus 15’ discussion)
Vesalius Talk Sunday, 9 October 2016, 17:30-18:45 30 mins
Title session Developing an effective relationship between basic scientists and medical oncologists
Introduction Matthias Preusser, AT
Speakers Richard Marais, UK – EACR President Fortunato Ciardiello, IT – ESMO President Maria Sibilia, AT Marina Garassino, IT
Vesalius Cocktail – 45’ Follows on immediately after talk
![Page 48: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/48.jpg)
48
YO Brunches YO Brunch 1 – 45’ Saturday 8 October, 11:00-12:00
Title EMA approval process for anticancer agents: What should the oncologist know?
Speaker Francesco Pignatti, UK
Session Coordinators
Raffaele Califano, UK Michiel Strijbos, BE
Lecture/disc time 45’
YO Brunch 2 – 45’ Sunday 9 October, 11:00-12:00
Title How to find the best literature for your paper: Pubmed and other academic databases
Speaker Elinor Harriss, UK
Session Coordinators
Jesus Corral, ES Mehmed Akif Ozturk, TR
Lecture/disc time 45’
YO Brunch 3 – 45’ Monday 10 October, 11:00-12:00
Title What makes a good review article? The Editors perspective
Lecture 1 Original articles
Speaker 1 Olivier Mir, FR
Lecture 2 Review
Speaker 2 Christoph Zielinski, AT
Session Coordinators
Sophie Postel-Vinay, FR Nikita Volkov, RU
Lecture/disc time 45’
![Page 49: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/49.jpg)
49
YO Forum Monday 10 October, 16:00-17:30 90mins
Title
Professional development and communication skills
Chair Leticia de Mattos-Arruda, ES
Co-Chair Susana Banerjee, UK
Title presentation 1 Presentation skills and dealing with media
Speaker 1 Duncan Hart, UK
Session Shooter Mila Petrova, BG
Lecture time 1 45’ with questions / interactive part
Title presentation 2 How to become an effective leader and create a strong team
Speakers Evandro de Azambuja BE
Erika Martinelli, IT
Session Shooter Camilla Qvortrup, DK
Lecture time 2 45’ with questions
YO Fellowship session Monday, 10 October 2016, 14:15-15:45 90mins
Title ESMO Fellowships and awards
Chair Christoph Zielinski, AT
Co-Chair Matthias Preusser, AT
Title presentation 1 Introduction to session
Speaker 1 Christoph Zielinski, AT
Lecture time 1 5’
Title presentation 2 The ESMO Fellowship Programme
(Importance of YO for ESMO and how ESMO addresses the needs of
YOs through YOC and focus on different ESMO fellowships available)
Speaker 2 Valentina Guarneri, IT
Lecture time 2 15’
Title presentation 3 Practical tips from a former fellow
(from Translational Research / Clinical Research)
Speaker 3 Daniela Kolarevic, RS
Lecture time 3 15’
Title presentation 4 Best fellowship project 1
Speaker 4 Elena Castro, ES
Lecture time 4 15’
Title presentation 5 Best fellowship project 2
Speaker 5 Angela Lamarca, UK
Lecture time 5 15’
Title presentation 6 Conclusions
Speaker 6 Matthias Preusser, AT
Lecture time 6 5’
Awards: Presentation of the ESMO 2016 Fellows and 2015 Best Exam
Award 2015
20’
![Page 50: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/50.jpg)
50
YO Mentorship session
Monday, 10 October 2016 – 09:30-10:30
60mins
Title ESMO Young Oncologists Mentorship session
Coordinators Michiel Strijbos, BE
Camilla Qvortrup, DK
Topic 1 x 2 tables Working in academia Practising quality onco
Table 1 Mentor
Table 2 Mentor
Roger Stupp, CH Enriqueta Felip, ES
Topic 2 x 2 tables Practicing oncologists
Table 3 Mentor
Table 4 Mentor
Sofia Braga, PT Stefan Rauh, LU
Topic 3 x 2 tables Industry as a career choice
Table 5 Mentor
Table 6 Mentor
Tom Lillie, UK Michelle Rashford, UK
![Page 51: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/51.jpg)
51
ESMO Congress, Copenhagen 2016
Special Session
Sunday, 9 October 2016 – 11:00-12:30
Title symposium
Practising quality oncology across Europe and beyond: How can we
get there? Existing projects and future outlooks
Chair / Co-Chair
Stefan Rauh, LU
Co-Chair
Dirk Arnold, DE
Title presentation 1
Introduction
Speaker 1
Dirk Arnold, DE
Lecture time 1
5’
Title presentation 2
Quality improvement in centre structures. Experience within the German Cancer Society accreditation system
Speaker 2
Johannes Bruns, DE
Lecture time 2
10’
Title presentation 3
What is meant by "quality in oncology care"?
Speaker 3
Patrick Castel, FR
Lecture time 3
10’
Title presentation 4
Accreditation and Designation of Comprehensive Cancer Centres in Europe, the OECI's challenge
Speaker 4
Simon Oberst, UK
Lecture time 4
10’
Title presentation 5
Round table panel discussion
Speaker 5
ALL
Lecture time 5ii
35’
Speaker 5
Q&A
Lecture time 5ii
15’
Title presentation 6
Conclusions
Speaker 6
Stefan Rauh, LU
Lecture time 6
5’
![Page 52: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/52.jpg)
52
ESMO Congress, Copenhagen 2016
Special Session
Friday, 7 October 2016 – 14:00-15:30
Title symposium Communication findings of clinical trials: The first 12 months from analysis
Chair / Co-Chair Matt Sydes, UK
Co-Chair Evandro de Azambuja, BE
Title presentation 1 Introduction
Speaker 1 Evandro de Azambuja, BE
Lecture time 1 5’
Title presentation 2 Disseminating results: What are we trying to achieve and who needs to hear?
Speaker 2 Annabelle South, UK
Lecture time 2 15’
Title presentation 3 What, when and how patients and the public want to know: New results and implications for practice
Speaker 3 Richard Stephens, UK
Lecture time 3 15’
Title presentation 4 The role of the press office and the role of the media
Speaker 4 Evandro de Azambuja, BE
Lecture time 4 15’
Title presentation 5 How clinical trial data leads to changes in practice: The perspective of the cost-effectiveness body
Speaker 5 Sarah Garner, UK
Lecture time 5 15’
Title presentation 6 Conclusions
Speaker 6 Matt Sydes, UK
Lecture time 6 10’
![Page 53: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/53.jpg)
53
ESMO Congress, Copenhagen 2016
Special Session
Monday, 10 October 2016 – 11:00-12:30
Title symposium
Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Chair / Co-Chair Johann de Bono, UK
Co-Chair Roger Stupp, CH
Title presentation 1 Introduction
Speaker 1 Roger Stupp, CH
Lecture time 1 5’
Title presentation 2 Developing drugs targeting the PI3K/AKT signalling
Speaker 2 Li Yan, US
Lecture time 2 20’
Title presentation 3 Pembrolizumab: Rapidly moving the field forward through industry-academic collaborations
Speaker 3 Paul Haluska, US
Lecture time 3 20’
Title presentation 4 Novel clinical trial designs incorporating genomics for developing anti-cancer drugs: Olaparib in prostate cancer
Speaker 4 Johann de Bono, UK
Lecture time 4 20’
Title presentation 5 The role of consortia and corporative groups in the modern era of cancer drug development
Speaker 5 Roger Stupp, CH
Lecture time 5 20’
Title presentation 6 Conclusions
Speaker 6 Johann de Bono, UK
Lecture time 6 5’
![Page 54: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/54.jpg)
54
ESMO Congress, Copenhagen 2016
Special Session
Monday 10 October 2016, 11:00-12:30
Title symposium Reporting clinical trials: Faculty of principles of clinical trials and systemic therapy
Chair / Co-Chair Christian Dittrich, AT
Co-Chair Denis Lacombe, BE
Title presentation 1 Introduction
Speaker 1 Christian Dittrich, AT
Lecture time 1 5’
Title presentation 2 Improving the reporting of adverse events
Speaker 2 Bostjan Seruga, SI
Lecture time 2 15’
Title presentation 3 Unplanned versus pre-specified subgroup analysis reporting
Speaker 3 Douglas G. Altman, UK
Lecture time 3 15’
Title presentation 4 Quality of meta-analyses and why they sometimes lead to different conclusions
Speaker 4 Jean-Pierre Pignon, FR
Lecture time 4 15’
Title presentation 5 Early reporting of efficacy endpoints and its potential impact: Biostatistical part
Speaker 5 Jan Bogaerts, BE
Lecture time 5 15’
Title presentation 6 Early reporting of efficacy endpoints and its potential impact: Clinical part
Speaker 6 Fatima Cardoso, PT
Lecture time 6 15’
Title presentation 6 Conclusions
Speaker 6 Denis Lacombe, BE
Lecture time 6 5’
![Page 55: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/55.jpg)
55
ESMO Congress, Copenhagen 2016
Special Session Sunday, 9 October 2016 – 14:45-16:15
Title symposium Clinical benefit of cancer drugs
Chair / Co-Chair
Elisabeth de Vries, NL
Co-Chair
Nathan Cherny, IL
Title presentation 1
Introduction
Speaker 1
Elisabeth de Vries, NL
Lecture time 1
5’
Title presentation 2
ESMO Magnitude of Clinical Benefit Scale (MCBS): version 1.1
Speaker 2
Nathan Cherny, IL
Lecture time 2
20’ including discussion
Title presentation 3
The different available approaches to qualify benefit of drugs in oncology
Speaker 3
Elisabeth de Vries, NL
Lecture time 3
20’ including discussion
Title presentation 4
Guidelines including grading of novel drugs with ESMO MCBS
Speaker 4
Andrés Cervantes, ES
Lecture time 4
20’ including discussion
Title presentation 5
Lecture to be defined
Speaker 5
Josep Tabernero, ES
Lecture time 5
20’ including discussion
Title presentation 6
Conclusions
Speaker 6
Elisabeth de Vries, NL
Lecture time 6
5’
![Page 56: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/56.jpg)
56
ESMO Congress, Copenhagen 2016
Special Session
Saturday 8 October 2016 – 09:30-10:30
Session Title Practising Oncologists “How I treat” session Managing side effects and treatment related to advanced colorectal cancer
Chair & Speaker Dirk Arnold, PT
Title presentation 1 Introduction
Speaker 1 Stefan Rauh, LU
Lecture time 1 5’
Title presentation 2 Managing treatment side effects in advanced colorectal cancer
- When to stop oxaliplatine for toxicity - What side effects are prohibitive to continue oxaliplatine? - Diarrhoea management in gi treatment - GI chemotherapy in cirrhotic patients (FOLFOX, FOLFIRI,
etc; dose adaptations? limits?) - Fatigue /toxicity during regorafenib treatment - Patient selection: Who would not benefit ?
-
Speaker 2 Dirk Arnold, PT
Lecture time 2 20’
Title presentation 3 Discussion
Speaker 3 Dirk Arnod, PT and Stefan Rauh, LU
Lecture time 3 35’
![Page 57: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/57.jpg)
57
ESMO Congress, Copenhagen 2016
Special Session Saturday 8 October 2016 – 15:00-16:00
Session Title Practising Oncologists “How I treat” session Managing issues in pancreatic cancer
Chair & Speaker Gábor Lakatos, HU
Pancreatic cancer: FOLFIRINOX in real life
- For which patient is it feasible? - Should FOLFIRINOX be used in the neoadjuvant or in the
palliative setting?
5’ Speaker & case presentation: Gábor Lakatos, HU
5’ Discussant: Michel Ducreux, FR
10’ General Discussion
Pancreatic cancer: Optimizing neoadjuvant therapy in borderline resectable cases
- Which chemotherapy regimen to choose? - How many cycles are needed?
5’ Speaker & case presentation: Gábor Lakatos, HU
5’ Discussant: Michel Ducreux, FR
10’ General Discussion
Borderline resectable pancreatic cancer
- Surgical aspects
5’ Speaker & case presentation: Gábor Lakatos, HU
5’ Discussant: Michel Ducreux, FR
10’ General Discussion
![Page 58: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/58.jpg)
58
ESMO Congress, Copenhagen 2016
Special Session Sunday, 9th October 16:30 – 18:30 90 mins (1h30) Session plus 30 mins Award Section
Title symposium
ESMO Integrated Oncology & Palliative Care Community Session
Chair / Co-Chair
Florian Strasser, CH
Co-Chair
Anna-Marie Stevens, UK
Title presentation 1
Introduction
Speaker 1
Florian Strasser, CH
Lecture time 1
5’
Title presentation 2 The global ESMO Designated Centers of Integrated Oncology and Palliative Care Network: Characteristics, indicators, work force
Speaker 2
David Hui, US
Lecture time 2
20’
Title presentation 3
Building the community: Curricula, educational material, and opportunities to become a double-boarded oncologist and palliative care specialist
Speaker 3
Gudrun Kreye, AU
Lecture time 3
20’
Title presentation 4
Integration of psychosocial oncology care in routine oncology
Speaker 4 Luzia Travado, PT
Lecture time 4
20’
Title presentation 5
Selection of innovative practices of integrated oncology and palliative care performed in designated centers
Speaker 5
Richard Berman, UK
Lecture time 5
20’
Title presentation 6
Conclusions
Speaker 6 Anna-Marie Stevens, UK
Lecture time 6
5’
Award Section 30’ Designated Centre and Palliative Care Fellowship Awards
Presenter Nathan Cherny, IL and Florian Strasser, CH
Presenter Fellowship Awards, Gudrun Kreye, AU
![Page 59: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/59.jpg)
59
ESMO Congress, Copenhagen 2016
Special Session
Sunday 9 October 2016 – 09:00-10:30
Title symposium
Women 4 Oncology
Chair / Co-Chair
Solange Peters, CH
Co-Chair
Sumitra Thongprasert, TH
Title presentation 1
Introduction and results of the 2016 W4O survey
Speaker 1
Solange Peters, CH
Lecture time 1
10’
Title presentation 2
The role of mentors and sponsorship in women’s careers
Speaker 2
Giuseppe Curigliano, IT
Lecture time 2
15’
Title presentation 3
What are the obstacles for female careers in oncology? Perspectives to help form the politics for political change
Speaker 3
Sandra Swain, US
Lecture time 3
15’
Title presentation 4
Imagine you were a woman: How would you plan and proceed with your career?
Speaker 4
Christoph Zielinski, AT
Lecture time 4
15’
Title presentation 5
Work–life balance: The need to develop policies to support flexibility
Speaker 5
Sonja Hammerschmid, AT
Lecture time 5
15’
Title presentation 8
W4O Award Presentation
Speaker 8
Christoph Zielinski, AT
Lecture time 8
2’
Title presentation 9
W4O Award Recipient (with PPT)
Speaker 9
Sumitra Thongprasert, TH
Lecture time 9
8’
Title presentation 10
Q&A and Closing remarks
Speaker 10
Solange Peters, CH
Lecture time 10’
10’
![Page 60: ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED … · Title presentation 2 Tumour evolution under the selective pressure of treatment Speaker 2 Charles Swanton, UK Lecture/disc](https://reader034.vdocuments.mx/reader034/viewer/2022042407/5f21965297f53137a8587385/html5/thumbnails/60.jpg)
60
ESMO Congress, Copenhagen 2016
Special Session proposed by ESO
Friday, 8 October 2016, 16:00-17:30
Title symposium
Active Surveillance for low risk prostate cancer
Chair / Co-Chair
Riccardo Valdagni, IT
Co-Chair
Alan Horwich, UK
Title presentation 1
Why do we need Active Surveillance? The problem of overdiagnosis, indolent cancer and overtreatment
Speaker 1
Monique Roobol, NL
Lecture time 1
20’
Title presentation 2
What do we mean by Active Surveillance? Definition, criteria for inclusion and management, overview of protocols open for recruitment
Speaker 2
Chris Bangma, NL
Lecture time 2
20’
Title presentation 3
What do we need to improve the selection and management? Genetic profiling and serum markers
Speaker 3
Anders Bjartell, SE
Lecture time 3
10’
Title presentation 4
What do we need to improve the selection and management? MRI and targeted biopsy
Speaker 4
Caroline Moore, UK
Lecture time 4
10’
Title presentation 5
Living with an untreated cancer. The quality of life of men on Active Surveillance
Speaker 5
Lara Bellardita, IT
Lecture time 5
10’
Title presentation 6
Discussion
Speaker 6
All
Lecture time 6
20’